Click here to access the analysis for Fluoxetine.

Note that this offer is in place prior to the beginning of the 5 month Dual listing transition period which commences 1 November 2019. Fluoxetine-Arrow will remain fully funded at existing schedule price until 31 March 2019.

We encourage you to continue to support the incumbent products until stocks are depleted or Sole Supply commences, whichever comes first.

ProPharma /PWR will implement automatic replacement for Fluoxetine Capsules and Tablets as stock are depleted or 31 March 2020, whichever comes first.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author